Eton PharmaceuticalsETON
Recorded

Eton Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hi, everyone. Good afternoon. Welcome to the 2026 Jefferies Healthcare Conference. Please welcome Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Sean BrynjelsenCEO

Thank you. Thank you. Thank you, everyone, for attending today.

Sean BrynjelsenCEO

I want to talk a little bit about Eton Pharma and what we do. It is actually pretty simple. Our company was founded in 2017, and at the time, we started out with a 505(b)(two) strategy, and about two years into that, decided to go all in on ultra-rare disease. We noticed that in the U.S., there are over 7,000 rare diseases, and less than 5% of them have any type of cure, treatment. A lot of parents with children that were just not being served by big pharma. I saw this as a great opportunity because you ended up where these patients were largely being ignored, and I just thought, "Well, if all these patients are being ignored, why is that?" They were being ignored because there were less than $50 million typically on a given product.

Sean BrynjelsenCEO

The market size was very small. Patient population might be 80 people, could be 12, could be a couple of thousand, but certainly far less than the FDA's definition of a rare disease, which is 200,000. For us, what this meant is you have this universe of products, you have a small patient base, mostly children, and you realize that there is thousands of these rare diseases with no treatment options. From my perspective, I thought we could build a unique business model. What we have done is we have proven that business model today. This is a business model that is unique. I think it took investors several years to figure that out, and the business model is to really build the largest ultra-rare disease portfolio in industry.

Sean BrynjelsenCEO

The second part of that was not just having the products, because having the products is one part, but getting the commitment to your patient in a way that was authentic and real, and unlike what big pharma does, where they tout all these wonderful programs you can apply through and jump through these hoops, but at the end of the day, the patient was not getting the product if they were not getting reimbursed or the insurance was not covering it. So, I decided a long time ago that if these kids need drug, they are going to get drug. We are going to make sure that the patient access that we give is unprecedented, and that we have done through the Eton Cares program. You will find out a little bit more about that later in my presentation. And innovative therapies. Some of the therapies are more innovative than others.

Sean BrynjelsenCEO

I'll talk a little bit about the product portfolio. I'm proud of all of these products because they're meaningful products. They're products that, for these patients, we have worked very closely with the advocacy groups, we work very closely with the caregivers, and we listen to the doctors on what they need. I do want to emphasize that our approach to bringing these products to market is almost agnostic as to how we get those products to market. It doesn't matter whether we're buying them or licensing them, we're developing them, whether they're small molecule, whether they're big molecule, that's all irrelevant. The patient doesn't care about that. They care about, does the product work? Does it treat my given disease? Can I get access to it? It's as simple as that. What you have is a differentiated business model based on these four pillars.

Sean BrynjelsenCEO

Diversified portfolio focus. My dream on this company is to have all the large therapeutic areas covered with products, for us to have teams in each of these therapeutic areas. That's building a diversified portfolio of industries, of assets, which are contrary to a typical industry approach, which is to say, "We're going to be in endocrinology. We're going to be the best in endocrinology. We want to build up. It's not in endocrinology, we don't want to be there." We want to focus on blockbuster products. If you look at most of the biotech companies out there, they're story stocks. If X, Y, and Z happens, we got this billion-dollar market ahead of us. X, Y, and Z rarely happens.

Sean BrynjelsenCEO

One of the aspects of this was to ensure that when we brought products to market, we would be able to do so with a high degree of certainty. Every product and project that we have done, we have brought that product to approval, whether that was partnering or whether that was internally developed. We have a unique growth engine, which is unlike any other. We have a track record of success with doing M&A and licensing. We today have more inbound licensing deals and transaction deals than I've ever seen. In fact, probably more than we can even contemplate. Part of that, I guess, is as you move into different therapeutic areas, you're going to get a lot of that in.

Sean BrynjelsenCEO

We do have to go through and figure out which ones are going to make a strategic fit, and I'll talk a little bit about how we select those deals. In conjunction with that, we end up having a number of internally developed products that emanate from parents' desires, physicians' desires, patient advocacy groups, which come up with ideas. We go to the agency, we work very closely with the FDA, and we think we can launch four products next year. When I say four products, I mean more than four products. This year, we launched three products. Previous year, we launched three products. We're on set to launch four or more products next year. The other aspect of this, as I touched on, was therapeutic area agnostic.

Sean BrynjelsenCEO

If there's a rare disease, ultra-rare disease product, why do I need to be locked into a given therapeutic area? Today, we're in multiple therapeutic areas. We're in metabolic, we're in endocrinology, we're in hematology. We just went into infectious diseases, the launch of IMPAVIDO. We just also now entered neurology with our licensing deal of LIBERVANT, which we are very excited about, and we think is going to be a fantastic product for patients. The other aspect of this, the final pillar of this, I guess you could say this table, is a lean operating model. I was talking to a CEO of a company recently, and he's like, "Well, how do you guys launch all these products with so few people?" My response to him was, "Well, why do you have so many people to launch one product?" It's not necessary.

Sean BrynjelsenCEO

If you have the right people, and we think we have the best in the business, you can launch products because people know what they're doing. We've launched many products before. I have our Chief Commercial Officer, the team we hire, we go out and we try to find the people that know what they're doing. At that point, it's with a patient focus in mind at the end of the day. That's what I care about beyond everything else. We have one of the broadest rare disease portfolios in industry. 12 approved products, six therapeutic areas. I'm not that excited by this chart. Some people would be. I just feel like there's so much more work to be done. I think that there'll come a day when we'll have 100 products up here.

Sean BrynjelsenCEO

If we keep growing and launching three, four products a year-over-year, which we will do, and we will largely even potentially do larger acquisitions, we will be in 12 different therapeutic areas. There is no reason we can't build this out. This is an infrastructure. It's a business strategy. This isn't a story stock where you're investing in because they're going to get this clinical result or they're going to have this inflection point. Don't ever invest in the company if you're looking for an invent-driven stock. This company is really something that you should be comfortable investing in and sitting on it for 10 years and coming back and being really happy with the return. The return and the investors is not why we're doing what we're doing.

Sean BrynjelsenCEO

We're doing this for the patients at the end of the day, and that's all a side effect of launching products on a year-over-year basis. I'm very excited about ET-900. This is a product that is actually, will be a spinoff of INCRELEX. They're in totally two different areas. INCRELEX is for a growth hormone disorder. There's only a couple hundred patients in the U.S. on that product, but some doctors from Baylor University and University of Chicago noticed that it has a mechanism of action to address infantile spasms, which is a severe neurological issue in babies primarily. These babies have 70 seizures a day. In the animal models, INCRELEX worked fabulously in terms of stopping those seizures.

Sean BrynjelsenCEO

We have now started a clinical study to expand the use of IGF-1 replacement therapy, and that will be our ET-900, and we hope to have clinical results announced in the first half of next year. That would be fantastic. I will not go into all the disease details. We do not have a lot of time to do that, but I do want to touch on that. The other products, I think the idea here that I am trying to convey is that when we entered neurology, we did not want just one trophy product, LIBERVANT, sitting in neurology, say, "We are in neurology." What we do is we want to build out that portfolio in each of these segments. You want to build out a business. I have got a general manager that is in charge of endocrinology. Think of that like a company.

Sean BrynjelsenCEO

She runs it, she has got people, so on and so forth. We have our back office support that handles all of it in terms of the quality, the regulatory, the logistics, but the sales, the marketing, the commercialization, these are different buckets. We took neurology and we added ET-900 into that. Similarly, when we bought GALZIN from Teva, this was a Wilson disease drug. It is a copper storage issue. Many of the patients were non-compliant because it causes GI discomfort, GI issues. If you had to take a medicine that was going to make you nauseous, how likely would you be to skip a dose? Probably pretty likely. This is three times a day. We decided, let us do a sustained release, a controlled release drug that will be done in the morning when you wake up and before you go to bed, and that is it.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day